Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion

Eye

Volumn 23, Issue 12, 2009, Pages 2215-2222

  Wu, W C ^a,b   Cheng, K C ^c   Wu, H J ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

Author keywords

Central retinal vein occlusion; Intravitreal bevacizumab; Intravitreal triamcinolone acetonide; Macular oedema

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE ACETONIDE;

ADULT; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; ENDOPHTHALMITIS; EYE INFLAMMATION; EYE TOXICITY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; MALE; MEDICAL RECORD; OPTICAL COHERENCE TOMOGRAPHY; RECURRENT DISEASE; RETINA DETACHMENT; RETINA MACULA EDEMA; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULA LUTEA; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY;

EID: 72749110039     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2008.429     Document Type: Article

References (41)

1. Hayreh SS. Classification of central retinal vein occlusion. Ophthalmology 1983; 90(5): 458-474.
2. Green WR, Chan CC, Hutchins GM, Terry JM. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc 1981; 79: 371-422.
3. Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Arch Ophthalmol 1997; 115(4): 486-491.
4. Evaluation of grid pattern photocoagulation for macular oedema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology 1995; 102(10): 1425-1433.
5. McAllister IL, Douglas JP, Constable IJ, Yu DY. Laserinduced chorioretinal venous anastomosis for nonischemic central retinal vein occlusion: evaluation of the complications and their risk factors. Am J Ophthalmol 1998; 126(2): 219-229.
6. Elman MJ, Raden RZ, Carrigan A. Intravitreal injection of tissue plasminogen activator for central retinal vein occlusion. Trans Am Ophthalmol Soc 2001; 99: 219-221; discussion 222-1213
7. Weiss JN, Bynoe LA. Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion. Ophthalmology 2001; 108(12): 2249-2257.
8. Mirshahi A, Roohipoor R, Lashay A, Mohammadi SF, Mansouri MR. Surgical induction of chorioretinal venous anastomosis in ischaemic central retinal vein occlusion: a non-randomised controlled clinical trial. Br J Ophthalmol 2005; 89(1): 64-69.
9. Opremcak EM, Bruce RA, Lomeo MD, Ridenour CD, Letson AD, Rehmar AJ. Radial optic neurotomy for central retinal vein occlusion: a retrospective pilot study of 11 consecutive cases. Retina 2001; 21(5): 408-415.
10. Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E. Intravitreal triamcinolone acetonide for macular ooedema due to central retinal vein occlusion. Br J Ophthalmol 2002; 86(2): 247-248.
11. Park CH, Jaffe GJ, Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular oedema associated with central retinal vein occlusion. Am J Ophthalmol 2003; 136(3): 419-425.
12. Ip MS, Gottlieb JL, Kahana A, Scott IU, Altaweel MM, Blodi BA et al. Intravitreal triamcinolone for the treatment of macular oedema associated with central retinal vein occlusion. Arch Ophthalmol 2004; 122(8): 1131-1136.
13. Cekic O, Chang S, Tseng JJ, Barile GR, Weissman H, Del Priore LV et al. Intravitreal triamcinolone treatment for macular oedema associated with central retinal vein occlusion and hemiretinal vein occlusion. Retina 2005; 25(7): 846-850. (Pubitemid 41456574)
14. Williamson TH, O'Donnell A. Intravitreal triamcinolone acetonide for cystoid macular oedema in nonischemic central retinal vein occlusion. Am J Ophthalmol 2005; 139(5): 860-866.
15. Gelston CD, Olson JL, Mandava N. Macular oedema in central retinal vein occlusion treated with intravitreal triamcinolone. Acta Ophthalmol Scand 2006; 84(3): 314-318.
16. Goff MJ, Jumper JM, Yang SS, Fu AD, Johnson RN, McDonald HR et al. Intravitreal triamcinolone acetonide treatment of macular oedema associated with central retinal vein occlusion. Retina 2006; 26(8): 896-901.
17. Gregori NZ, Rosenfeld PJ, Puliafito CA, Flynn Jr HW, Lee JE, Mavrofrides EC et al. One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular oedema secondary to central retinal vein occlusion. Retina 2006; 26(8): 889-895.
18. Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL et al. Intravitreal bevacizumab (Avastin) treatment of macular oedema in central retinal vein occlusion: a short-term study. Retina 2006; 26(3): 279-284.
19. Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, Ying H, Do DVet al. Ranibizumab for macular oedema due to retinal vein occlusions; implication of VEGF as a critical stimulator. Mol Ther 2008; 16(4): 791-799.
20. Vinores SA, Youssri AI, Luna JD, Chen YS, Bhargave S, Vinores MA et al. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol Histopathol 1997; 12(1): 99-109.
21. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 1998; 105(3): 412-416.
22. Fischer S, Renz D, Schaper W, Karliczek GF. In vitro effects of dexamethasone on hypoxia-induced hyperpermeability and expression of vascular endothelial growth factor. Eur J Pharmacol 2001; 411(3): 231-243.
23. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular oedema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005; 36(4): 336-339.
24. Kreutzer TC, Alge CS,Wolf AH, Kook D, Burger J, Strauss R et al. Intravitreal bevacizumab for the treatment of macular ooedema secondary to branch retinal vein occlusion. Br J Ophthalmol 2008; 92(3): 351-355.
25. Wu L, Arevalo JF, Roca JA, Maia M, Berrocal MH, Rodriguez FJ et al. Comparison of two doses of intravitreal bevacizumab (avastin) for treatment of macular oedema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina 2008; 28(2): 212-219.
26. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular oedema. Retina 2006; 26(9): 999-1005.
27. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular oedema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007; 114(4): 743-750. (Pubitemid 46483714)
28. Ferrara DC, Koizumi H, Spaide RF. Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol 2007; 144(6): 864-871. (Pubitemid 350122344)
29. McCuen II BW, Bessler M, Tano Y, Chandler D, Machemer R. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 1981; 91(6): 785-788.
30. Hida T, Chandler D, Arena JE, Machemer R. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 1986; 101(2): 190-195.
31. Kivilcim M, Peyman GA, El-Dessouky ES, Kazi AA, Cheema R, Hegazy H. Retinal toxicity of triamcinolone acetonide in silicone-filled eyes. Ophthalmic Surg Lasers 2000; 31(6): 474-478.
32. Luthra S, Narayanan R, Marques LE, Chwa M, Kim DW, Dong J et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 2006; 26(5): 512-518.
33. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006; 26(3): 257-261.
34. Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006; 26(3): 262-269.
35. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26(3): 270-274.
36. Agrawal S, Agrawal J, Agrawal TP. Conjunctival ulceration following triamcinolone injection. Am J Ophthalmol 2003; 136(3): 539-540.
37. Jonas JB, Spandau UH, Schlichtenbrede F. Short-term complications of intravitreal injections of triamcinolone and bevacizumab. Eye 2008; 22(4): 590-591.
38. Nelson ML, Tennant MT, Sivalingam A, Regillo CD, Belmont JB, Martidis A. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003; 23(5): 686-691.
39. Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003; 121(9): 1279-1282.
40. Hsu J, Kaiser RS, Sivalingam A, Abraham P, Fineman MS, Samuel MA et al. Intravitreal bevacizumab (Avastin) in central retinal vein occlusion. Retina 2007; 27(8): 1013-1019.
41. Priglinger SG, Wolf AH, Kreutzer TC, Kook D, Hofer A, Strauss RW et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina 2007; 27(8): 1004-1012.